Quick Links

Breadcrumbs Navigation

Home > Clinical Trials > Adult Clinical Trials - Lung Cancer

Jumbo Large Regular Text:

Adult Clinical Trials - Lung Cancer

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Ann-Marie Peters, RN BSN or Karen Dukelow, RN OCN at 919-681-4768 or 919-684-8926 fax

Items 1 - 14 of 14

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer Cachexia (NSCLC-C): An Extension Study
Principal Investigator: Amy Abernethy
Phase: N/A

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients with NSCLC-C - ROMANA 2
Principal Investigator: Amy Abernethy
Phase: Phase III
Phone: (919) 668-3891

CALGB 140202 The CALGB Lung Cancer Tissue Bank
Principal Investigator: Jeffrey Crawford
Phase: Other
Phone: 919-684-1988

CALGB 30901: Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients with Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy
Principal Investigator: Jeffrey Crawford
Phase: Phase II
Phone: 919-681-4768

CALGB 30607: Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
Principal Investigator: Jeffrey Crawford
Phase: Phase III
Phone: 919-681-4768

CALGB 30801: A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer
Principal Investigator: Jeffrey Crawford
Phase: Phase III
Phone: 919-681-4768

An Open-Label Two-Stage Study of Orally Administered BKM120 in Patients with Metastatic Non-Small Cell Lung Cancer with Activated PI3K Pathway
Principal Investigator: Frank Dunphy
Phase: Phase II
Phone: 919-681-4768

Phase I Dose Escalation Study of Accelerated Fractionation With Esophageal Sparing Using Intensity-Modulated Radiation Therapy for Locally-Advanced Thoracic Malignancies Including a Prospective Assessment of Esophageal Motion and Radiation-Induced Esophageal Injury
Principal Investigator: Christopher Kelsey
Phase: Phase I
Phone: 919-668-3726

A Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients (PHACS)
Principal Investigator: Gary Lyman
Phase: Phase III
Phone: 919-684-6180

A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib,Ipilimumab or as Monotherapy in First-Line or in Switch Maintenance in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)
Principal Investigator: Neal Ready
Phase: Phase I

An Open-Label randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Principal Investigator: Neal Ready
Phase: Phase III
Phone: 919-681-4768

An Open-label Randomized Phase III Trial of BMS-936558 versus Deocetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Principal Investigator: Neal Ready
Phase: Phase III
Phone: 919-681-4768

A Phase I/II study of MGCD265 in Combination with Erlotinib or Docetaxel in subjects with Advanced Malignancies and in Subjects with Advanced Non-small Cell Lung Camcer (NSCLC)
Principal Investigator: John Strickler
Phase: Phase I

Impact of Aggressive versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients with Malignant Pleural Effusions
Principal Investigator: Momen Wahidi
Phase: Phase IV
Phone: 919-668-3812